How biotech is reshaping weight loss, psychedelics, and women’s health

Biotech innovation and regulation are the focus as BIO looks back at BIO 2025 discussions on GLP-1 weight loss, medical psychedelics, and women’s health, then connects them to emerging evidence. For weight loss, GLP-1 therapies are framed as effective for chronic disease control, but experts at BIO 2025 emphasize that long term results require addressing muscle mass, especially for older patients. For medical psychedelics, the page highlights panel remarks that some patients may not respond with remission after a single dose, motivating ongoing clinical trial efforts. Regulatory pace is positioned as a key bottleneck, with commentary that agencies like the FDA cannot be experts in every disease, so biotechs help through scientific and disease-area education. The women’s health section points to modeling work suggesting HPV vaccination plus regular Pap testing could eliminate cervical cancer in South Korea by 2034 under high screening and vaccination coverage assumptions.